Key result
Pfizer-BioNTech mRNA COVID-19 vaccination in adolescents aged 12-17 years resulted in a myopericarditis incidence of 97 per million in males and 16 per million in females.
Why the study?
Does mRNA COVID-19 vaccination increase the risk of myopericarditis in adolescents 12-17 years of age?
Cohort (n=261,334)
Yes
Does mRNA COVID-19 vaccination increase the risk of myopericarditis in adolescents 12-17 years of age?
The incidence of myopericarditis after mRNA COVID-19 vaccination in Danish male adolescents was 97 per million, which appears higher than initial reports from US passive surveillance systems.
May warrant enhanced surveillance in adolescent males; extends passive surveillance estimates with active cohort data.
In this prospective nationwide multicenter study from Denmark, myopericarditis after Pfizer-BioNTech mRNA COVID-19 vaccination was identified in 13 males and 2 females between May 15 and September 15, 2021, among 133,477 vaccinated males and 127,857 vaccinated females 12-17 years of age, equaling 97 males and 16 females per million. In conclusion, the incidence of myopericarditis after COVID-19 vaccination among males appears higher than reports from the United States.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a cohort in Myopericarditis (n=261,334). Pfizer-BioNTech mRNA COVID-19 vaccine vs. Unvaccinated background population was evaluated on Incidence of myopericarditis. Pfizer-BioNTech mRNA COVID-19 vaccination in adolescents aged 12-17 years resulted in a myopericarditis incidence of 97 per million in males and 16 per million in females.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: